The Manila Times44 分钟
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
VBP301, a Phase 1/2, multicenter, open-label, first-in-human study of VCAR33, is a transplant donor-derived anti-CD33 CAR-T ...